Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465–79.

Article  PubMed  PubMed Central  Google Scholar 

Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018;14:405–17.

Article  CAS  PubMed  Google Scholar 

Ogdie A, Myers K, Mansfield C, et al. Experiences and treatment preferences in patients with psoriatic arthritis: a cross-sectional study in the ArthritisPower Registry. Rheumatol Ther. 2022;9:735–51.

Article  PubMed  PubMed Central  Google Scholar 

Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700–12.

Article  PubMed  Google Scholar 

Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71:5–32.

Article  PubMed  Google Scholar 

Clunie G, McInnes IB, Barkham N, et al. Long-term effectiveness of tumour necrosis factor-alpha inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study. Rheumatol Adv Pract. 2018;2:rky042.

Article  PubMed  PubMed Central  Google Scholar 

Mease PJ, Karki C, Liu M, et al. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open. 2019;5:e000880.

Article  PubMed  PubMed Central  Google Scholar 

Xie Y, Liu Y. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review. Clin Exp Dermatol. 2022;47:1627–35.

Article  PubMed  Google Scholar 

Ogdie A, Coates LC, Mease P. Measuring outcomes in psoriatic arthritis. Arthritis Care Res (Hoboken). 2020;72(Suppl 10):82–109.

Article  PubMed  Google Scholar 

Tubach F, Ravaud P, Beaton D, et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol. 2007;34:1188–93.

PubMed  PubMed Central  Google Scholar 

Karmacharya P, Stull C, Stephens-Shields A, et al. Responsiveness and minimum clinically important difference in patient-reported outcome measures among patients with psoriatic arthritis: a prospective cohort study. Arthritis Care Res (Hoboken). 2023;75:2182–9.

Article  PubMed  Google Scholar 

Coates LC, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81:359–69.

Article  CAS  PubMed  Google Scholar 

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline. Guideline for good clinical practice E6(R3). 2025. Available at: https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf

Institute for Quality and Efficiency in Health Care (IQWiG). General Methods Version 6.1; 2022. p. 174. Available at: https://www.iqwig.de/methoden/general-methods_version-6-1.pdf

Cella D, Yount S, Sorensen M, et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32:811–9.

PubMed  Google Scholar 

Mease PJ, Woolley JM, Bitman B, et al. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011;38:2461–5.

Article  PubMed  Google Scholar 

Ware JE, Kosinski M, Keller SD, SF-36 Physical and Mental Health Summary Scales: a user’s manual. Boston: Health Assessment Lab, New England Medical Center; 1994.

Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics. 2004;22:27–38.

Article  PubMed  Google Scholar 

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.

Article  CAS  PubMed  Google Scholar 

Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230:27–33.

Article  CAS  PubMed  Google Scholar 

Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores [abstract P-59]. Br J Dermatol. 2002;147(suppl 62):50.

Google Scholar 

Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Investig Dermatol. 2005;125:659–64.

Article  CAS  PubMed  Google Scholar 

Skougaard M, Jorgensen TS, Rifbjerg-Madsen S, et al. Relationship between fatigue and inflammation, disease duration, and chronic pain in psoriatic arthritis: an observational DANBIO registry study. J Rheumatol. 2020;47:548–52.

Article  CAS  PubMed  Google Scholar 

Nymand L, Kristensen LE, Thomsen SF, et al. Characteristics and drivers of fatigue in patients with psoriasis and psoriatic arthritis: a cross-sectional study. J Am Acad Dermatol. 2024;91:57–63.

Article  PubMed  Google Scholar 

Husted JA, Tom BD, Schentag CT, et al. Occurrence and correlates of fatigue in psoriatic arthritis. Ann Rheum Dis. 2009;68:1553–8.

Article  CAS  PubMed  Google Scholar 

Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405–17.

Article  CAS  PubMed  Google Scholar 

Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418–31.

Article  CAS  PubMed  Google Scholar 

Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394:831–9.

Article  CAS  PubMed  Google Scholar 

Reich K, Gordon KB, Strober BE, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185:1146–59.

Article  CAS  PubMed  Google Scholar 

Curtis JR, Deodhar A, Soriano ER, et al. Early improvements with guselkumab associate with sustained control of psoriatic arthritis: post hoc analyses of two phase 3 trials. Rheumatol Ther. 2024;11(6):1501–1517. https://doi.org/10.1007/s40744-024-00702-0.

Article  PubMed  PubMed Central  Google Scholar 

Rahman P, Mease PJ, Helliwell PS, et al. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Res Ther. 2021;23:190.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ogdie A, Michaud K, Nowak M, et al. Patient’s experience of psoriatic arthritis: a conceptual model based on qualitative interviews. RMD Open. 2020;6(3):e001321. https://doi.org/10.1136/rmdopen-2020-001321.

Article  PubMed  PubMed Central  Google Scholar 

Tillett W, Dures E, Hewlett S, et al. A multicenter nominal group study to rank outcomes important to patients, and their representation in existing composite outcome measures for psoriatic arthritis. J Rheumatol. 2017;44:1445–52.

Article  PubMed  Google Scholar 

Coates LC, van der Horst-Bruinsma IE, Lubrano E, et al. Sex-specific differences in patients with psoriatic arthritis: a systematic review. J Rheumatol. 2023;50:488–96.

Article  PubMed